Theravance Biopharma, Inc. (TBPH) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 53.81M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $53.81M | (m) |
| 2026-03-31 | (m) | $114.54M | (m) |
| 2025-12-31 | (m) | $105.89M | (m) |
| 2025-09-30 | (m) | $29.34M | (m) |
| 2025-06-30 | (m) | $13.03M | (m) |
| 2025-03-31 | (m) | $-58.33M | (m) |
| 2024-12-31 | (m) | $-56.42M | (m) |
| 2024-09-30 | (m) | $-49.40M | (m) |
| 2024-06-30 | (m) | $-45.65M | (m) |
| 2024-03-31 | (m) | $-44.77M | (m) |
| 2023-12-31 | (m) | $-55.19M | (m) |
| 2023-09-30 | (m) | $-57.05M | (m) |
| 2023-06-30 | (m) | $868.54M | (m) |
| 2023-03-31 | (m) | $875.99M | (m) |
| 2022-12-31 | (m) | $872.13M | (m) |
| 2022-09-30 | (m) | $850.46M | (m) |
| 2022-06-30 | (m) | $-101.48M | (m) |
| 2022-03-31 | (m) | $-145.69M | (m) |
| 2021-12-31 | (m) | $-199.43M | (m) |
| 2021-09-30 | (m) | $-225.83M | (m) |
| 2021-06-30 | (m) | $-264.16M | (m) |
| 2021-03-31 | (m) | $-274.64M | (m) |
| 2020-12-31 | (m) | $-278.02M | (m) |
| 2020-09-30 | (m) | $-285.19M | (m) |
| 2020-06-30 | (m) | $-269.98M | (m) |
| 2020-03-31 | (m) | $-246.93M | (m) |
| 2019-12-31 | (m) | $-236.46M | (m) |
| 2019-09-30 | (m) | $-221.03M | (m) |
| 2019-06-30 | (m) | $-222.04M | (m) |
| 2019-03-31 | (m) | $-223.02M | (m) |
| 2018-12-31 | (m) | $-215.52M | (m) |
| 2018-09-30 | (m) | $-252.26M | (m) |
| 2018-06-30 | (m) | $-259.70M | (m) |
| 2018-03-31 | (m) | $-285.17M | (m) |
| 2017-12-31 | (m) | $-285.40M | (m) |
| 2017-09-30 | (m) | $-265.82M | (m) |
| 2017-06-30 | (m) | $-232.90M | (m) |
| 2017-03-31 | (m) | $-213.84M | (m) |
| 2016-12-31 | (m) | $-190.67M | (m) |
| 2016-09-30 | (m) | $-168.16M | (m) |
| 2016-06-30 | (m) | $-181.52M | (m) |
| 2016-03-31 | (m) | $-181.90M | (m) |
| 2015-12-31 | (m) | $-182.22M | (m) |
| 2015-09-30 | (m) | $-201.70M | (m) |
| 2015-06-30 | (m) | $-208.88M | (m) |
| 2015-03-31 | (m) | $-219.49M | (m) |
| 2014-12-31 | (m) | $-237.04M | (m) |
| 2014-09-30 | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) |
| 2013-12-31 | (m) | $-156.28M | (m) |
| 2013-09-30 | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) |
| 2012-12-31 | (m) | $-9.57M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |